Thananopavarn C, Golub M S, Eggena P, Barrett J D, Sambhi M P
Am J Cardiol. 1982 Jan;49(1):153-8. doi: 10.1016/0002-9149(82)90289-2.
Sixteen patients with uncomplicated essential hypertension were treated with 0.2 mg of clonidine three times daily as the sole antihypertensive drug. Blood pressure decreased from 167 +/- 4/105 +/- 2 to 139 +/- 3/89 +/- 2 mm Hg (mean +/- standard error of the mean) after 1 week (p less than 0.001) and remained at 140 +/- 3/90 +/- 2 mm Hg after 3 months of therapy. There were no significant changes in cardiac output, blood volume, renal blood flow or glomerular filtration rate during clonidine therapy. Clonidine significantly decreased plasma catecholamines and there was a linear correlation between the change in blood pressure and decreases in plasma catecholamine concentration (r = 0.61, p less than 0.001). There was also a significant correlation between the decreases in heart rate and blood pressure (r = 0.78, p less than 0.001). It is concluded that clonidine can be used effectively and safely as the sole agent in the treatment of mild to moderate hypertension.
16例单纯性原发性高血压患者，每日3次服用0.2毫克可乐定作为唯一的抗高血压药物。1周后血压从167±4/105±2降至139±3/89±2毫米汞柱（平均值±平均标准误差）（p<0.001），治疗3个月后维持在140±3/90±2毫米汞柱。可乐定治疗期间心输出量、血容量、肾血流量或肾小球滤过率无显著变化。可乐定显著降低血浆儿茶酚胺，血压变化与血浆儿茶酚胺浓度降低之间呈线性相关（r = 0.61，p<0.001）。心率下降与血压下降之间也存在显著相关性（r = 0.78，p<0.001）。结论是可乐定可有效且安全地作为轻度至中度高血压治疗的单一药物。
